Media Summary: ... a pharmaceutical grade form of esterified epa used in the Michael Miller, MD, an investigator on the Want to learn one of the basics of heart attack & stroke prevention... for free? Get free access to the CV inflammation course by ...

Reduce It Trial - Detailed Analysis & Overview

... a pharmaceutical grade form of esterified epa used in the Michael Miller, MD, an investigator on the Want to learn one of the basics of heart attack & stroke prevention... for free? Get free access to the CV inflammation course by ... A discussion on recent data updates from the Deepak L. Bhatt, MD, MPH, Executive Director of Interventional Cardiovascular Program in the Heart & Vascular Center at ... Study author Deepak Bhatt, MD, with Howard Weintraub, MD, Kim Eagle, MD, and John Higgins, MD Medpage Today: ...

Prof. Raul Santos gives his opinion on the results of the ... MD, ScM, vice chair of the program committee for Scientific Sessions 2018, comments on the results of the Icosapent ethyl, which has an expected FDA decision date in September, is one of the most exciting topics at the American ... Experts in the field of cardiovascular risk

Photo Gallery

ESC TV at AHA 2018 - REDUCE-IT Trial
REDUCE IT Trial
The REDUCE-IT Trial and CV Outcomes
Michael Miller, MD: REDUCE-IT Trial
The REDUCE-IT trial - Omega 3 (5 min summary) 2018- FORD BREWER MD MPH
REDUCE-IT Trial Data Updates: Key Takeaways
REDUCE-IT clinical trial results | Brigham and Women's Hospital
The Primary Results of the REDUCE-IT Trial - Medpage Today
REDUCE-IT Trial Data Updates: Key Takeaways
What is your perspective of the results of the REDUCE-IT trial with high dose eicosapentaenoic acid?
REDUCE IT Commentary
Robert Busch, MD: REDUCE-IT Trial Implications, Icosapent Ethyl for Diabetes Patients
Sponsored
Sponsored
View Detailed Profile
ESC TV at AHA 2018 - REDUCE-IT Trial

ESC TV at AHA 2018 - REDUCE-IT Trial

Reduction

REDUCE IT Trial

REDUCE IT Trial

... a pharmaceutical grade form of esterified epa used in the

Sponsored
The REDUCE-IT Trial and CV Outcomes

The REDUCE-IT Trial and CV Outcomes

An overview of the

Michael Miller, MD: REDUCE-IT Trial

Michael Miller, MD: REDUCE-IT Trial

Michael Miller, MD, an investigator on the

The REDUCE-IT trial - Omega 3 (5 min summary) 2018- FORD BREWER MD MPH

The REDUCE-IT trial - Omega 3 (5 min summary) 2018- FORD BREWER MD MPH

Want to learn one of the basics of heart attack & stroke prevention... for free? Get free access to the CV inflammation course by ...

Sponsored
REDUCE-IT Trial Data Updates: Key Takeaways

REDUCE-IT Trial Data Updates: Key Takeaways

A discussion on recent data updates from the

REDUCE-IT clinical trial results | Brigham and Women's Hospital

REDUCE-IT clinical trial results | Brigham and Women's Hospital

Deepak L. Bhatt, MD, MPH, Executive Director of Interventional Cardiovascular Program in the Heart & Vascular Center at ...

The Primary Results of the REDUCE-IT Trial - Medpage Today

The Primary Results of the REDUCE-IT Trial - Medpage Today

Study author Deepak Bhatt, MD, with Howard Weintraub, MD, Kim Eagle, MD, and John Higgins, MD Medpage Today: ...

REDUCE-IT Trial Data Updates: Key Takeaways

REDUCE-IT Trial Data Updates: Key Takeaways

A discussion on recent data updates from the

What is your perspective of the results of the REDUCE-IT trial with high dose eicosapentaenoic acid?

What is your perspective of the results of the REDUCE-IT trial with high dose eicosapentaenoic acid?

Prof. Raul Santos gives his opinion on the results of the

REDUCE IT Commentary

REDUCE IT Commentary

... MD, ScM, vice chair of the program committee for Scientific Sessions 2018, comments on the results of the

Robert Busch, MD: REDUCE-IT Trial Implications, Icosapent Ethyl for Diabetes Patients

Robert Busch, MD: REDUCE-IT Trial Implications, Icosapent Ethyl for Diabetes Patients

Icosapent ethyl, which has an expected FDA decision date in September, is one of the most exciting topics at the American ...

The REDUCE-IT Study

The REDUCE-IT Study

Experts in the field of cardiovascular risk